二氯化镭223对去势抵抗性前列腺癌伴骨转移患者血细胞计数骨痛程度和血PSA f-PSA和OPG的影响

doi:10.3969/j.issn.1006-6233.2025.01.030

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (1208 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To investigate the influence of radium-223 dichloride on blood cell count, bone pain degree, and serum prostate-specific antigen (PSA), free PSA (f-PSA), and osteoprotegerin (OPG) in patients with castration-resistant prostate cancer (CRPC) complicated by bone metastasis. Methods: A total of 122 patients with CRPC and bone metastasis at the First Affiliated Hospital of Xi'an Jiaotong University were studied from February 2020 to December 2023. They were randomly divided into an observation group (n=61, radium-223 dichloride + conventional treatment) and a control group (n=61, conventional treatment). After 6 months, blood cell count, bone pain degree, serum factors, efficacy, and adverse reactions were compared between the groups. Results: The counts of red blood cells, NK cells, CD4⁺ cells, and platelets decreased in both groups after treatment, with statistically significant differences before and after treatment (P<0.05). After treatment, the VAS, PSA, f-PSA, and OPG levels were reduced in both groups, with statistically significant differences between pre- and post-treatment levels (P<0.05). The total effective rate was higher in the observation group than in the control group (P<0.05). The incidence rates of adverse reactions such as gastrointestinal discomfort, muscle soreness or fatigue, abnormal body temperature, and peripheral edema, as well as the total incidence rate (6.56%, 13.11%, 9.84%, 11.48%, 40.98% in the observation group), were not statistically different from those in the control group (8.20%, 9.84%, 11.48%, 3.28%, 32.79%) (P>0.05). Conclusion: For CRPC patients with bone metastasis, radium-223 dichloride is beneficial for improving blood cell count and OPG levels, alleviating bone pain severity, reducing PSA and f-PSA levels, and enhancing treatment efficacy. It also demonstrates high safety and has value for promotion.

Key words： Radium-223 dichloride Prostate cancer Bone metastasis Prostate-specific antigen

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Cite this article:

URL:

http://www.hbyxzzs.cn/EN/10.3969/j.issn.1006-6233.2025.01.030 OR http://www.hbyxzzs.cn/EN/Y2025/V31/I1/165

[1] 张月,权春姬,金雪梅,等.EpCAM和HDAC6在前列腺癌中的表达及其对前列腺癌细胞迁移的影响[J].临床与实验病理学杂志,2024,40(4):402-410.
[2] 阳锦秋,辛储林,尹光芬,等.丙泊酚和瑞马唑仑对前列腺癌细胞增殖的影响[J].临床麻醉学杂志,2024,40(5):520-526.
[3] 田志崇,衡立,董婧婷,等.前列腺癌骨转移关键基因的生物信息学分析[J].中国免疫学杂志,2023,39(9):1885-1892.
[4] 何伟,何文强.恩扎卢胺一线治疗去势抵抗性前列腺癌[J].中华泌尿外科杂志,2021,42(2):30-32.
[5] 杨晓剑,李鑫,吴开杰,等.镭-223治疗前列腺癌骨转移初探[J].现代泌尿外科杂志,2022,27(2):133-136.
[6] 中国抗癌协会泌尿肿瘤专业委员会.中国去势抵抗性前列腺癌诊治专家共识[J].浙江医学,2016,38(14):1133-1136,1145.
[7] 中国前列腺癌研究协作组.前列腺癌药物去势治疗随访管理中国专家共识(2024版)[J].中华肿瘤杂志,2024,46(4):285-295.
[8] 陆开艺,付海生,江志勇.去势抵抗性前列腺癌患者血清睾酮水平与多西他赛临床疗效及预后的关系[J].中国性科学,2024,33(5):10-13.
[9] 严永峰,孙致强,张景军,等.乙酰半乳糖氨基转移酶7对前列腺癌细胞迁移、侵袭和增殖的作用及机制[J].中华实验外科杂志,2024,41(6):1185-1188.
[10] Hyvakka A,Kaariainen OS,Utriainen T,et al.Radium-223 dichloride treatment in metastatic castration-resistant prostate cancer in finland:a real-world evidence multicenter study[J].Cancer Med,2023,12(4):4064-4076.
[11] 杨振宇,龙星博,王骏,等.因卡膦酸二钠治疗骨转移去势抵抗性前列腺癌的疗效及安全性研究[J].现代泌尿生殖肿瘤杂志,2023,15(5):286-289.
[12] 彭伟,李运改,许静,等.血清炎症因子联合PSA、f-PSA可辅助诊断前列腺癌[J].检验医学,2023,38(9):849-854.
[13] 李志清,胡明.老年前列腺癌患者雄性激素阻断治疗期间骨密度降低的影响因素分析[J].医学临床研究,2023,40(3):385-388.